AVRO

In a report released today, Gil Blum from Needham maintained a Buy rating on Avrobio (AVRO - Research Report), with a price target of $6.00. The company's shares opened today at $0.90.According to TipRanks, Blum is an analyst with an average return of -24.6% and a 25.25% success rate. Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Rocket Pharmaceuticals, and Mereo Biopharma Group Plc.Currently, the analyst consensus on Avrobio is a Moderate Buy with an average price target of $6.00, which is a 566.67% upside from current levels.
https://www.tipranks.com/news/blurbs/needham-reaffirms-their-buy-rating-on-avrobio-avro?utm_source=advfn.com&utm_medium=referral